{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Vericel Corporation"},"Symbol":{"label":"Symbol","value":"VCEL"},"Address":{"label":"Address","value":"64 SIDNEY STREET, CAMBRIDGE, Massachusetts, 02139, United States"},"Phone":{"label":"Phone","value":"+1 617 588-5555"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases."},"CompanyUrl":{"label":"Company Url","value":"https://www.vcel.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Dominick C. Colangelo","title":"President, Chief Executive Officer & Director"},{"name":"Jonathan Mark Hopper","title":"Chief Medical Officer"},{"name":"Michael Halpin","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}